Surgical rates in the era of biological therapy: Up, down or unchanged?

Pablo Olivera, Antonino Spinelli, Corinne Gower-Rousseau, Silvio Danese, Laurent Peyrin-Biroulet

Research output: Contribution to journalReview articlepeer-review


Purpose of review The aim of this review is to summarize data regarding surgical trends in inflammatory bowel disease in the prebiologic and biologic era, with a focus on population-based studies and randomized controlled trials (RCTs). Recent findings There is paucity of data in RCTs regarding surgical rates, with only a few clinical trials reporting them. From the available data, meta-analyses of RCTs have concluded that antitumor necrosis α agents (anti-TNF) reduce surgical rates in ulcerative colitis and Crohn's disease. A large body of evidence from population-based studies from different regions of the world is available to evaluate surgical trends before and after the introduction of anti-TNF agents. The risk of surgery decreased significantly over the past six decades; these decreasing trends continued in the biologic era, which might indicate a potential beneficial disease-modifying effect of biologics. There is lack of data with nonanti-TNF biologics (i.e. anti-integrins and ustekinumab) regarding the risk of surgery. Summary Although data from population-based studies and available RCTs suggest a protective effect from surgery of anti-TNF agents, definitive conclusions should be drawn only when more disease-modifying trials with different biologics and treatment strategies become available.

Original languageEnglish
Pages (from-to)246-253
Number of pages8
JournalCurrent Opinion in Gastroenterology
Issue number4
Publication statusPublished - Jul 1 2017


  • biologics
  • colectomy
  • inflammatory bowel disease
  • surgery

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Surgical rates in the era of biological therapy: Up, down or unchanged?'. Together they form a unique fingerprint.

Cite this